BWX Technologies

BWX Technologies

BWX Technologies operates as a publicly traded nuclear engineering and manufacturing firm listed on the New York Stock Exchange. Its roots trace to the Babcock & Wilcox company, which built nuclear reactors for the US Navy beginning in the 1950s. The modern entity emerged as an independent firm in 2015, when Babcock & Wilcox split into two companies — BWX Technologies took the nuclear operations, while the legacy power generation business became Babcock & Wilcox Enterprises (per SEC filings, 2015). The firm's primary manufacturing complex sits in Lynchburg, Virginia, with additional facilities in Ohio, Indiana, Canada, and the United Kingdom. The firm's core business is the design, manufacture, and servicing of nuclear reactors for the US Navy's Virginia-class submarines and Ford-class aircraft carriers — a role so singular that the government owns the reactor design and BWXT operates under long-term contracts (per Department of Defense budget documents, 2024). Beyond naval propulsion, BWX Technologies develops small modular reactors for commercial power generation through its subsidiary BWXT Advanced Nuclear Technologies, and produces medical isotopes for cancer treatment via the BWXT Medical subsidiary. The company also operates a government services segment that manages nuclear sites for the US Department of Energy. Confirmed commercial partners include the Wyoming Energy Authority, which selected BWXT's BWRX-300 SMR design for potential deployment at the Naughton Power Plant site (per the firm, 2021). The company reported $2.5 billion in revenue for its fiscal year 2024, with a backlog of approximately $3.1 billion as of December 31, 2024 (per BWX Technologies annual report, 2024). It employs roughly 6,700 people across its facilities. The firm maintains no separate philanthropic foundation listed publicly, though its operations are subject to rigorous government and nuclear regulatory oversight. BWX Technologies' structural moat rests on its position as the sole manufacturer of nuclear propulsion reactors for the US Navy — a capability the US government has not licensed to any other private firm. This creates a revenue stream that is both opaque (classified) and non-discretionary (tied to shipbuilding schedules). The company's move into commercial SMRs and medical isotopes represents a diversification bet on the same core competency, but the classified naval work remains the profit engine and the barrier to entry for any competitor.